Medical Treatment of Ankylosing Spondylitis

Overview

Journal Hip Pelvis

Date 2016 Aug 19

PMID 27536570

Citations 11

Authors

Kyoung-Ho Moon

Young-Tae Kim

Affiliations

Soon will be listed here.

Abstract

The diagnosis of ankylosing spondylitis is often delayed due to ambiguous clinical manifestations and strict diagnostic criteria. However, imaging techniques such as magnetic resonance imaging have been found effective for the early diagnosis of non-radiographic sacroiliitis. New tumor necrosis factor alpha (TNF-α) inhibitors have good efficacy for patients with persistently high disease activity despite conventional nonsteroidal anti-inflammatory drug treatment. Thus, early diagnosis and aggressive treatments are essential for ankylosing spondylitis patients. Because many patients complain of musculoskeletal pains, especially around the sacroiliac joint area, hip specialists should be informed of up-to-date knowledge. In this review, we discuss new diagnostic criteria for ankylosing spondylitis, administration methods of TNF-α inhibitors, and the long-term follow-up results for patients treated with TNF-α inhibitors.

Citing Articles

Current Concepts and Medical Management for Patients with Radiographic Axial Spondyloarthritis.

Baek S, Oh S, Shim B, Yoo J, Hwang J, Kim T Hip Pelvis. 2024; 36(4):234-249.

PMID: 39620565 PMC: 11638751. DOI: 10.5371/hp.2024.36.4.234.

Causality between Ankylosing Spondylitis and osteoarthritis in European ancestry: a bidirectional Mendelian randomization study.

Lu Y, Lu D, Zhang H, Li H, Yu B, Zhang Y Front Immunol. 2024; 15:1297454.

PMID: 38380324 PMC: 10876785. DOI: 10.3389/fimmu.2024.1297454.

Molecular Characterisation of Blood Microbiome in Patients with Ankylosing Spondylitis and Healthy Controls.

Mohsen Hammad D, Abdulazeez Alhamad O, Mahdy Obiad Khzal A, Muslim Alameedy F Med J Islam Repub Iran. 2023; 37:84.

PMID: 38021395 PMC: 10657266. DOI: 10.47176/mjiri.37.84.

The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis.

Alzahrani Z, Bashrahil B, Alzahrani R, Alharthy F Cureus. 2023; 15(2):e35360.

PMID: 36974243 PMC: 10039670. DOI: 10.7759/cureus.35360.

Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis.

Girbash E, Abdelwahab S, Atef R, Sherif H, Abdeldayem H, Atta D BMC Pregnancy Childbirth. 2023; 23(1):35.

PMID: 36650451 PMC: 9847183. DOI: 10.1186/s12884-023-05364-4.

References

Bruner V, Atteno M, Spano A, Scarpa R, Peluso R . Biological therapies for spondyloarthritis. Ther Adv Musculoskelet Dis. 2014; 6(3):92-101. PMC: 4040940. DOI: 10.1177/1759720X14535512. View

Maxwell L, Zochling J, Boonen A, Singh J, Veras M, Tanjong Ghogomu E . TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; (4):CD005468. PMC: 11200207. DOI: 10.1002/14651858.CD005468.pub2. View

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E . 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70(6):896-904. PMC: 3086052. DOI: 10.1136/ard.2011.151027. View

Barkham N, Keen H, Coates L, OConnor P, Hensor E, Fraser A . Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009; 60(4):946-54. DOI: 10.1002/art.24408. View

Rudwaleit M, Metter A, Listing J, Sieper J, Braun J . Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006; 54(2):569-78. DOI: 10.1002/art.21619. View

Khalessi A, Oh B, Wang M . Medical management of ankylosing spondylitis. Neurosurg Focus. 2008; 24(1):E4. DOI: 10.3171/FOC/2008/24/1/E4. View

Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G . Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005; 7(3):R439-44. PMC: 1174938. DOI: 10.1186/ar1693. View

Adams K, Bombardier C, van der Heijde D . Safety and efficacy of on-demand versus continuous use of nonsteroidal antiinflammatory drugs in patients with inflammatory arthritis: a systematic literature review. J Rheumatol Suppl. 2012; 90:56-8. DOI: 10.3899/jrheum.120343. View

Evans D, Spencer C, Pointon J, Su Z, Harvey D, Kochan G . Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011; 43(8):761-7. PMC: 3640413. DOI: 10.1038/ng.873. View

10.

Miedany Y, Youssef S, Ahmed I, El Gaafary M . The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006; 101(2):311-7. DOI: 10.1111/j.1572-0241.2006.00384.x. View

11.

Khan M . Update on spondyloarthropathies. Ann Intern Med. 2002; 136(12):896-907. DOI: 10.7326/0003-4819-136-12-200206180-00011. View

12.

Wanders A, van der Heijde D, Landewe R, Behier J, Calin A, Olivieri I . Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52(6):1756-65. DOI: 10.1002/art.21054. View

13.

Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H . Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995; 38(4):499-505. DOI: 10.1002/art.1780380407. View

14.

Sieper J, van der Heijde D, Dougados M, Brown L, Lavie F, Pangan A . Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2011; 71(5):700-6. PMC: 3329233. DOI: 10.1136/annrheumdis-2011-200358. View

15.

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J . Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013; 15(3):R67. PMC: 4060369. DOI: 10.1186/ar4244. View

16.

Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong R, Kupper H . Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008; 58(7):1981-91. DOI: 10.1002/art.23606. View

17.

Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester G . Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011; 50(9):1690-9. DOI: 10.1093/rheumatology/ker194. View

18.

Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A . Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002; 61 Suppl 3:iii8-18. PMC: 1766729. DOI: 10.1136/ard.61.suppl_3.iii8. View

19.

Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans B, Vlahos B, Pedersen R . Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010; 28(2):238-45. View

20.

Bennett A, McGonagle D, OConnor P, Hensor E, Sivera F, Coates L . Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008; 58(11):3413-8. DOI: 10.1002/art.24024. View